N/A N=781 Building a Multidisciplinary Bridge Across the Quality Chasm in Thoracic Oncology
Lung Cancer
Primary: Thoroughness of Invasive Staging, Multidisciplinary (MD) vs Serial Care (SC) — 108; 168; 70; 180 Participants — p=0.0007
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=46 S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors
Lung Cancer
Primary: Feasibility of Treating Patients With Stage IIB/IIIB Pancoast Tumors With a Regimen of Cisplatin and Etoposide Plus Concurrent Radiotherapy Followed by Surgical…
Phase 2 N=41 Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Define the Maximum Tolerated Dose (MTD) Using This Dose Schedule. — 20; 28.6; 33.3 Percentage subj w dose limiting toxicity
Phase 2 N=28 Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC) · Stage IV NSCLC · Metastatic NSCLC
Primary: Objective Response Rate — 0; 1 participants
Phase 2 N=647 Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Carcinoma, Non-Small-Cell Lung · Carcinoma, Small Cell Lung · Carcinoma, Thymic
Primary: Percentage of Enrolled Participants Testing Positive for Genomic Abnormality — 28.5; 44.2; 0; 24.9 percentage of participants
N/A N=204 The Detection Of Circulating Tumor Cells (CTC) In Patients With NSCLC Undergoing Definitive Radiotherapy Or Chemoradiotherapy
Non-small Cell Lung Cancer
Primary: To Describe the Pattern of CTCs Before and After Definitive Radiotherapy for Each Treatment Stratum — 3.9; 9.1; 9.1; 9.1 CTCs/mL
N/A N=39 Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer
Breast Cancer
Primary: Success Rate in Removing Sentinel Lymph Nodes by Thoracoscopy — 31 participants
Phase 2 N=53 The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Phase 2 N=22 Hyperpolarized Xenon Gas MR Imaging in NSCLC Radiotherapy
Non-small Cell Lung Cancer
Primary: Number of Participants With a Change From Baseline in Ventilation Map Using Hyperpolarized Xe-129 MR Imaging — 6 Participants — p=0.041
Phase 3 N=72 Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer
Malignant Pleural Effusion
Primary: Number of Participants With "Complete Response" and "Partial Response" — 17; 2; 13; 15 participants
Phase 2 N=27 Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)
Lung Cancer
Primary: Median Progression Free Survival (PFS) — 7.5 months
Phase 2 N=71 Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Lung Cancer
Primary: Mediastinal Nodal Clearance After Completion of Induction Chemoradiotherapy With or Without Panitumumab. — 68.2; 48.7 percentage of participants — p=0.96
N/A N=39 Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease
Lung Cancer
Primary: To Prospectively Collect Data on Chest CT Screening for Patients at Increase Lung-cancer Risk After Hodgkin's Disease. — 0 participants
N/A N=12 Study of Tarceva and Targretin in Stage I-II Lung Cancer
Carcinoma, Non-small-cell Lung
Primary: Number of Participants With Change in Expression Level of EGFR. — 3; 7 Participants
Phase 2 N=15 Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Progression Free Survival — 9.4 months
Phase 2 N=4 Trimodality Management of T1b Esophageal Cancers
Esophageal Cancer
Primary: Pathologic Complete Response (PCR) Rate
Phase 2 N=69 Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma
Esophageal Carcinoma
Primary: Median Recurrence Free Survival Time — 23.1 months
Early Phase 1 N=21 Bronchoscopic Cryo-Immunotherapy of Lung Cancer
Advanced Non-small Cell Lung Cancer
Primary: Percentage of Successful Performances Among Patients in Whom BCI is Attempted — 100 Percentage of participants
Phase 3 N=518 Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer
Non-Small Cell Lung Cancer
Primary: Overall Survival — 8.31; 8.51 Months
Phase 2 N=24 Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer
Primary: Percentage of Subjects With Detectable Circulating T Cells After Treatment — 16.7 Percentage of participants
Phase 2 N=19 Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
Lung Cancer
Primary: Toxic Death Rate — NA Participants
N/A N=24 Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes
Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8 · Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8 · Clinical Stage I Esophageal Adenocarcinoma AJCC v8
Primary: Proportion of Participants With a Cardiac Event at 12 Months — 0.6818 proportion of participants
N/A N=38 Stereotactic Body Radiation Therapy (SBRT) for Lung Tumors
Lung Cancer
Primary: Disease Status — 84; 78; 55; 54 percentage of participants
Phase 2 N=88 Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
Thymic Carcinoma · Non-small Cell Lung Cancer · Refractory Thoracic Tumors
Primary: Recommended Phase II Combination Dose in Phase I (Per Common Terminology Criteria for Adverse Events (CTCAE) Criteria Version 5) — 200 mg
N/A N=35 Stereotactic Body Radiation Therapy in Stage II/III Non Small Cell Lung Cancer
Lung Cancer
Primary: Boost Dose Toxicity — 5 Participants
Phase 2 N=48 Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer
Lung Neoplasms · Ovarian Neoplasms · Cervix Neoplasms
Primary: Geometric Mean of Maximum Concentration of the Drug (Cmax) — 1315; 1093; 1060; 1026 Cmax (ng/mL)
N/A N=116 Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy
Lung Cancer
Primary: Number of Participants With Overall Survival (OS) at 3 Years — 31; 70 Participants
Phase 2 N=68 TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer · Lung Cancer
Primary: Time To First Disease Progression — 14 Month
Phase 2 N=172 Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy
Non-small Cell Lung Cancer
Primary: Overall Survival (OS) Time — 32.4; 32.2 Months — p=0.828
Phase 2 N=60 Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer
Lung Cancer
Primary: Mediastinal Nodal Clearance Rate — 27 participants